2. Protein Tyrosine Kinase/RTK Apoptosis Membrane Transporter/Ion Channel Neuronal Signaling
  3. VEGFR Caspase Calcium Channel
  4. COX-2-IN-55

COX-2-IN-55 (compound 1) 是一种口服有效的 Celecoxib (HY-14398) 类似物，具有广谱的抗癌活性和较弱的 COX-2 抑制作用。COX-2-IN-55 可特异性抑制 SERCA2，增加 caspase-3 裂解和 DR5 水平，从而激活 GRP78，抑制三阴性乳腺癌 (TNBC) 发展。COX-2-IN-55 还可以下调血管生成标志物 VEGF-α 和 IL-8 的水平，抑制微血管的生成。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

COX-2-IN-55 Chemical Structure

COX-2-IN-55 Chemical Structure

CAS No. : 2649115-80-8

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

COX-2-IN-55 相关抗体

Top Publications Citing Use of Products

查看 VEGFR 亚型特异性产品:

查看所有亚型
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

查看 Caspase 亚型特异性产品:

查看所有亚型
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

查看 Calcium Channel 亚型特异性产品:

查看所有亚型
N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

COX-2-IN-55 (compound 1) is an orally active, Celecoxib (HY-14398)-based analog with broad-spectrum anticancer activity and weak COX-2 inhibition. COX-2-IN-55 specifically inhibits SERCA2, increases caspase-3 cleavage and DR5 levels, thereby activating GRP78 and inhibiting the development of triple-negative breast cancer (TNBC). COX-2-IN-55 can also downregulate the levels of angiogenic markers VEGF-α and IL-8, inhibiting the formation of microvessels[1].

IC50 & Target

Caspase 3

 

VEGFR1

 

体外研究
(In Vitro)

COX-2-IN-55 (compound 1) 抑制 MDA-MB-231 细胞、MDA-MB-468 细胞、4T1 细胞、T47D 细胞和 MCF-7 细胞的活力，EC50 分别为 14.99 μM，14.26 μM，11.23 μM，17.3 μM，和 25.02 μM[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

COX-2-IN-55 相关抗体:
体内研究
(In Vivo)

COX-2-IN-55 (25 mg/kg/天，50 mg/kg/天；po；28 天) 在 MDA-MB-231 异种移植的 nu/nu 裸鼠模型中具有显著抗肿瘤特性，最高造成 85% 的肿瘤衰退[1]。
100 mg/kg/天 COX-2-IN-55 剂量下，处理 48 天后对小鼠不产生显著的生化或组织学毒性[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

486.51

Formula

C24H21F3N4O2S
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

COX-2-IN-55 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

COX-2-IN-552649115-80-8VEGFRCaspaseCalcium ChannelVascular endothelial growth factor receptorCa2+ channelsCa channelsInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
COX-2-IN-55
目录号：
HY-171992
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z